Singapore markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.47-0.03 (-0.40%)
At close: 04:00PM EDT
7.47 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 466.15M
Enterprise value 240.75M
Trailing P/E 315.25
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)163.93
Price/book (mrq)1.98
Enterprise value/revenue 50.55
Enterprise value/EBITDA -10.84

Trading information

Stock price history

Beta (5Y monthly) 2.35
52-week change 3105.22%
S&P500 52-week change 326.27%
52-week high 313.70
52-week low 32.65
50-day moving average 38.85
200-day moving average 36.34

Share statistics

Avg vol (3-month) 3603.02k
Avg vol (10-day) 3285.73k
Shares outstanding 562.15M
Implied shares outstanding 662.4M
Float 838.53M
% held by insiders 11.40%
% held by institutions 199.19%
Shares short (15 Apr 2024) 42.53M
Short ratio (15 Apr 2024) 44.35
Short % of float (15 Apr 2024) 45.08%
Short % of shares outstanding (15 Apr 2024) 44.08%
Shares short (prior month 15 Mar 2024) 42.39M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-3,213.78%

Management effectiveness

Return on assets (ttm)-28.56%
Return on equity (ttm)-44.84%

Income statement

Revenue (ttm)2.81M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)27.20%
Gross profit (ttm)N/A
EBITDA -108.49M
Net income avi to common (ttm)-97.33M
Diluted EPS (ttm)-1.58
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)236.22M
Total cash per share (mrq)3.81
Total debt (mrq)10.82M
Total debt/equity (mrq)4.60%
Current ratio (mrq)17.71
Book value per share (mrq)3.80

Cash flow statement

Operating cash flow (ttm)-90.97M
Levered free cash flow (ttm)-56.72M